These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29278613)

  • 1. Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV.
    Brophy J; Bitnun A; Alimenti A; Lapointe N; Samson L; Read S; Karatzios C; Dobson S; Moses E; Blitz S; Lipsky NG; Ogilvie G; Walmsley S; Raboud J; Money D;
    Pediatr Infect Dis J; 2018 Jun; 37(6):595-597. PubMed ID: 29278613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM).
    Hidalgo-Tenorio C; Ramírez-Taboada J; Gil-Anguita C; Esquivias J; Omar-Mohamed-Balgahata M; SamPedro A; Lopez-Ruz M; Pasquau J
    AIDS Res Ther; 2017 Jul; 14(1):34. PubMed ID: 28720147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine.
    Money DM; Moses E; Blitz S; Vandriel SM; Lipsky N; Walmsley SL; Loutfy M; Trottier S; Smaill F; Yudin MH; Klein M; Harris M; Cohen J; Wobeser W; Bitnun A; Lapointe N; Samson L; Brophy J; Karatzios C; Ogilvie G; Coutlée F; Raboud J;
    Vaccine; 2016 Sep; 34(40):4799-806. PubMed ID: 27544584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status.
    Mugo NR; Eckert L; Magaret AS; Cheng A; Mwaniki L; Ngure K; Celum C; Baeten JM; Galloway DA; Wamalwa D; Wald A
    Vaccine; 2018 Nov; 36(46):7025-7032. PubMed ID: 30297124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
    Mugo N; Ansah NA; Marino D; Saah A; Garner EI
    Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1.
    Cespedes MS; Kang M; Kojic EM; Umbleja T; Godfrey C; Webster-Cyriaque JY; Masih R; Firnhaber C; Grinsztejn B; Saah A; Cu-Uvin S; Aberg JA
    Papillomavirus Res; 2018 Dec; 6():15-21. PubMed ID: 30118852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men.
    Van Damme P; Meijer CJLM; Kieninger D; Schuyleman A; Thomas S; Luxembourg A; Baudin M
    Vaccine; 2016 Jul; 34(35):4205-4212. PubMed ID: 27354258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of 2 vs 3 Doses of the Quadrivalent Human Papillomavirus Vaccine in Girls Aged 9 to 13 Years After 60 Months.
    Ogilvie G; Sauvageau C; Dionne M; McNeil S; Krajden M; Money D; Dobson S
    JAMA; 2017 Apr; 317(16):1687-1688. PubMed ID: 28444267
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
    MacIntyre CR; Shaw P; Mackie FE; Boros C; Marshall H; Barnes M; Seale H; Kennedy SE; Moa A; Hayen A; Chughtai AA; O'Loughlin EV; Stormon M
    Vaccine; 2016 Aug; 34(36):4343-50. PubMed ID: 27406936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AIDS Malignancy Consortium 054: Safety and Immunogenicity of the Quadrivalent Vaccine in Indian Women Living With HIV.
    Palefsky JM; Poongulali S; Lensing S; Lee J; Da Costa M; Chein A; Beulah F; Murugavel KG; Kumarasamy N
    J Acquir Immune Defic Syndr; 2021 Jun; 87(2):875-881. PubMed ID: 33587509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, V and VD.
    Praditpornsilpa K; Kingwatanakul P; Deekajorndej T; Rianthavorn P; Susantitaphong P; Katavetin P; Tiranathanakul K; Srisawat N; Tungsanga K; Eiam-Ong S; Townamchai N
    Nephrol Dial Transplant; 2017 Jan; 32(1):132-136. PubMed ID: 26932687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults.
    Giacomet V; Penagini F; Trabattoni D; Viganò A; Rainone V; Bernazzani G; Bonardi CM; Clerici M; Bedogni G; Zuccotti GV
    Vaccine; 2014 Sep; 32(43):5657-61. PubMed ID: 25149430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine.
    Levin MJ; Huang S; Moscicki AB; Song LY; Read JS; Meyer WA; Saah AJ; Richardson K; Weinberg A;
    Vaccine; 2017 Mar; 35(13):1712-1720. PubMed ID: 28238631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women.
    Kojic EM; Kang M; Cespedes MS; Umbleja T; Godfrey C; Allen RT; Firnhaber C; Grinsztejn B; Palefsky JM; Webster-Cyriaque JY; Saah A; Aberg JA; Cu-Uvin S
    Clin Infect Dis; 2014 Jul; 59(1):127-35. PubMed ID: 24723284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of quadrivalent HPV vaccine dose spacing on immunologic response in women living with HIV.
    McClymont E; Ogilvie G; Albert A; Johnston A; Raboud J; Walmsley S; Lipsky N; Loutfy M; Trottier S; Smaill F; Yudin MH; Klein MB; Harris M; Wobeser W; Bitnun A; Kakkar F; Samson L; Brophy J; Karatzios C; Money D;
    Vaccine; 2020 Mar; 38(15):3073-3078. PubMed ID: 32147300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa.
    Mugo N; Eckert LO; Odero L; Gakuo S; Ngure K; Celum C; Baeten JM; Barnabas RV; Wald A
    Vaccine; 2021 Jul; 39(33):4751-4758. PubMed ID: 33485644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus.
    Dhar JP; Essenmacher L; Dhar R; Magee A; Ager J; Sokol RJ
    Vaccine; 2017 May; 35(20):2642-2646. PubMed ID: 28404357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men.
    Ellsworth GB; Lensing SY; Ogilvie CB; Lee JY; Goldstone SE; Berry-Lawhorn JM; Jay N; Stier EA; Logan JS; Einstein MH; Saah A; Mitsuyasu RT; Aboulafia D; Palefsky JM; Wilkin TJ
    Papillomavirus Res; 2018 Dec; 6():11-14. PubMed ID: 29807211
    [No Abstract]   [Full Text] [Related]  

  • 20. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
    Faust H; Toft L; Sehr P; Müller M; Bonde J; Forslund O; Østergaard L; Tolstrup M; Dillner J
    Vaccine; 2016 Mar; 34(13):1559-1565. PubMed ID: 26896686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.